Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: Results from a clinical practice database

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2725-2728

  Lazaridou, Marie Noëlle ^a,b   Montgomery, Donald I ^a   Ho, Whye Onn ^a   Jaberoo, David ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Fixed combination; Latanoprost; Ocular hypertension; Primary open angle glaucoma

Indexed keywords

BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; TIMOLOL;

AGED; ARTICLE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PRESSURE MEASUREMENT; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DATABASES, FACTUAL; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; TIMOLOL;

EID: 55549088577     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802312567     Document Type: Article

References (16)

1. European Glaucoma Society. Terminology and guidelines for glaucoma, 2nd ed. Savona, Italy: DOGMA®, Srl; 2003.
2. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
3. Toris CB, Camras CB, Yablonski ME. Effects of PhYA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100: 1297-304
4. Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977;95:601-4
5. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978; 96:2045-8
6. Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefe's Arch Clin Exp Ophthalmol 1998;236:577-81
7. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy versus monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915-22
8. Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe's Arch Clin Exp Ophthalmol 2002;240:893-9.
9. Lazaridis A, Lazaridou M-N. Applied medical statistics. Thessaloniki: Biblioekdotiki; 1999. p. 98-102.
10. Ray WA, O'Day DM, Head S, et al. Statistical analysis for experimental models of ocular disease: continuous response measures. Curr Eye Res 1985;5:585-97
11. Hamacher T, Schinzel M, Schölzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005% timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol 2004;88:1295-8
12. Konstas AGP, Bányai L, Blask K-D, et al. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J Ocul Pharmacol Ther 2004;20:375-82
13. Olander K, Zimmerman TJ, Downes N, et al; Xalacom/ Latanoprost Study Group. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther 2004;26: 1619-29.
14. Konstas AGP, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005;123:898-902
15. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-13
16. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56